Feb 14, 2017 12:44 pm UTC| Business
GAAP Operating Income was $0.8 million; Adjusted EBITDA reached $19.2 Million PETAH TIKVA, Israel, Feb. 14, 2017 -- Gilat Satellite Networks Ltd. (NASDAQ:GILT) (TASE:GILT), a worldwide leader in satellite networking...
Melco Crown Entertainment Announces Earnings Release Date
Feb 14, 2017 12:34 pm UTC| Business
MACAU, Feb. 14, 2017 -- Melco Crown Entertainment Limited (Nasdaq:MPEL) (“Melco Crown Entertainment” or the “Company”), a developer, owner and operator of casino gaming and entertainment resort facilities in Asia, today...
Feb 14, 2017 12:30 pm UTC| Business
HOUSTON, Feb. 14, 2017 -- PLx Pharma Inc. (PLx), a late-stage specialty pharmaceutical company developing next-generation nonsteroidal anti-inflammatory drugs and other pharmaceutical agents today announced that the...
Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Results
Feb 14, 2017 12:30 pm UTC| Business
DUBLIN, Ireland, Feb. 14, 2017 -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced it will report its fourth quarter and full year 2016 financial results on Tuesday, March 7, 2017, before the market open. A...
Lincoln Electric Reports Fourth Quarter and Full Year 2016 Results
Feb 14, 2017 12:30 pm UTC| Business
Fourth Quarter and Full Year 2016 Highlights● Fourth quarter EPS of $0.81; Full year 2016 EPS of $2.91 and Adjusted EPS of $3.29● Fourth quarter operating income margin resilient at 14.7%● Record average operating working...
NexImmune Acquired by a Consortium of Private Investors Led by Former Celgene and Medtronic CEOs
Feb 14, 2017 12:30 pm UTC| Business
GAITHERSBURG, Md., Feb. 14, 2017 -- NexImmune, a biopharmaceutical company developing novel immuno-therapeutics based on the Artificial Immune (AIM™) nanotechnology platform, today announced the completion of the...
Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model
Feb 14, 2017 12:30 pm UTC| Business
Data Published in Neuropharmacology RADNOR, Pa., Feb. 14, 2017 -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...